Mardepodect (hydrochloride)

Mardepodect (hydrochloride)

• CAS Number: 2070014-78-5
• UNSPSC Description: Mardepodect hydrochloride (PF-2545920 hydrochloride) is a potent, orally active and selective PDE10A inhibitor with an IC50 of 0.37 nM, with >1000-fold selectivity over other PDEs. Mardepodect hydrochloride can cross the blood-brain barrier[1][2].
• Target Antigen: Phosphodiesterase (PDE)
• Type: Reference compound
• Related Pathways: Metabolic Enzyme/Protease
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/PF-2545920-hydrochloride.html
• Purity: 99.94
• Solubility: DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: CN1N=C(C2=CC=C(OCC3=NC4=CC=CC=C4C=C3)C=C2)C(C5=CC=NC=C5)=C1.Cl[H]
• Molecular Weight: 428.91
• References & Citations: [1]Wilson JM et al. Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in D2 neurons than in D1 neurons in the neostriatum. Neuropharmacology. 2015 Dec;99:379-86.|[2]Verhoest PR et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem. 2009 Aug 27;52(16):5188-96.Patent. US20230111925A1.|Toxicol Appl Pharmacol. 2024 Apr 28:486:116945.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: Phase 2